Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewGenIvf (NIVF) Common Equity (2022 - 2025)

NewGenIvf (NIVF) has disclosed Common Equity for 4 consecutive years, with $26.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 1853.78% to $26.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.0 million through Dec 2025, up 1853.78% year-over-year, with the annual reading at $26.0 million for FY2025, 1853.78% up from the prior year.
  • Common Equity for Q4 2025 was $26.0 million at NewGenIvf, up from -$1.5 million in the prior quarter.
  • The five-year high for Common Equity was $26.0 million in Q4 2025, with the low at -$1.5 million in Q4 2024.
  • Average Common Equity over 4 years is $7.0 million, with a median of $1.7 million recorded in 2022.
  • The sharpest move saw Common Equity surged 3123.54% in 2023, then crashed 145.65% in 2024.
  • Over 4 years, Common Equity stood at $100683.0 in 2022, then skyrocketed by 3123.54% to $3.2 million in 2023, then plummeted by 145.65% to -$1.5 million in 2024, then surged by 1853.78% to $26.0 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $26.0 million, -$1.5 million, and $3.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.